All peptide-derivatives were labeled with 125I and tested for binding in comparison to the radiolabeled native CaIX-P1 on CA IX positive renal cell carcinoma SKRC 52 cells (Figure 1). This evidence concerns the gene CA9 and hereditary clear cell renal cell carcinoma.